Venkatesh Nathamuni
Analyst · Citigroup
Thank you, Bob, and good afternoon, everyone. Please turn to Slide #7, where I'll walk through our results for Q3. Gross revenue increased more than 34% year-over-year, and adjusted net revenue, which excludes pass-through revenue grew by over 8%. Q3 adjusted EBITDA was $367 million, up 17%, with our margin at 15.2% or 109 basis points higher year-over-year. This resulted in adjusted EPS increasing 14% year-over-year. Consolidated backlog was up more than 27% year-over-year to a record $29 billion with our trailing 12-month book-to-bill at 1.4x. Book-to-bill was strong again in Q3, driven by good awards activity across our end markets with standout performance in the advanced manufacturing, environmental and transportation sectors. Additionally, on a year-over-year basis, net revenue and gross profit in backlog increased 11% and 14%, respectively, during Q3. We are demonstrating faster organic growth in the business today and strong recent awards activity positions us well as we look ahead to fiscal year '27. Regarding our performance by end market in Infrastructure and Advanced Facilities, let's turn to Slide #8. At a high level, we continue to see strong growth rates in Life Sciences and Advanced Manufacturing as well as in critical infrastructure during Q3. Focusing on life sciences and advanced manufacturing, net revenue grew 24% in Q3, our highest growth rate since we began reporting end markets in late 2024. Strong performance in the data center and semiconductor sectors contributed to substantial year-on-year growth, and we anticipate that this trend will continue in Q4. We're seeing high demand for new projects across life sciences and advanced manufacturing, setting us up well for the new fiscal year. Shifting to Critical Infrastructure, net revenue increased 9% year-over-year. Critical Infrastructure trends remained similar to Q2 with Transportation and Energy and Power activity leading to strong growth versus last year. We continue to expect Critical Infrastructure to grow in the mid- to high single-digit range over the medium term. Net revenue growth in our Water & Environmental end market was a little more than 1%. Net revenue growth for water remains strong. And as we indicated last quarter, we did continue to face year-over-year headwinds in the environmental sector. On a positive note, we're forecasting growth for the Water & Environmental end market to sequentially improve in Q4 based on good awards activity in the quarter. In summary, strong Life Sciences and Advanced Manufacturing performance during Q3 was complemented by good demand across the majority of our sectors. Moving now to Slide #9, I'll provide a brief overview of our segment financials. In Q3, I&AF operating profit increased 14% year-over-year on 10% net revenue growth. PA Consulting operating profit increased 2% on flattish revenue and operating margin, again came in strong at above 22%. Both segments saw only a minor operating profit growth impact from foreign exchange during the quarter. Focusing on PA, the segment experienced some temporary disruption from the recent change in governmental leadership in the U.K., which delayed project start dates. Importantly, we are already seeing a return to normal, and our forecast indicates solid quarter-on-quarter revenue growth in Q4, supported by recent awards activity, new project commencements as well as performance quarter-to-date. Now moving on to Slide 10. We provide an overview of cash generation and our balance sheet. For Q3, we generated $541 million in adjusted free cash flow which removes the impact of $110 million in payments related to proceeds for the PA transaction as we had indicated last quarter. This brings year-to-date adjusted free cash flow to $633 million. Please note, we will not make adjustments to free cash flow in Q4 and will return to providing guidance for reported free cash flow margin in fiscal year '27. Focusing on capital returns, we remain aggressive buyers of our shares during Q3 to take advantage of the dislocation in our share price. As a result, our total repurchases through Q3 rose to $614 million, which combined with dividends paid, puts us on track to return more than 100% of free cash flow to our shareholders for the second consecutive year. This brings total share repurchases since the beginning of fiscal year '25 to $1.4 billion, and we see continued runway moving forward, given our strong outlook for free cash flow. Shifting now to the balance sheet. At the end of Q3, our net leverage ratio declined to 1.8x, achieving our target for net leverage to be below 2.0x, a quarter early, and we still plan to delever to approximately 1.5x by the end of fiscal year '27. Please turn to Slide 11 for our updated fiscal year '26 outlook. We're increasing our fiscal year '26 adjusted net revenue growth range to 9.5% to 10% year-over-year, narrowing our adjusted EBITDA margin range to 14.7% to 14.8%, raising our adjusted EPS range to $7.20 to $7.30 and raising our adjusted free cash flow margin forecast to 8%. Notably, our outlook for fiscal year '26 now implies nearly 19% year-on-year growth in adjusted EPS at the midpoint. As it pertains to Q4, we expect our adjusted EBITDA margin to be approximately 16%, with year-over-year net revenue growth of approximately 14%. Furthermore, we expect our tax rate to be roughly 27.5% and a quarterly free cash flow to be approximately $150 million. Overall, we're very pleased with our year-to-date performance and our Q4 outlook highlights that we expect a strong finish to fiscal year '26. With that, I'll turn the call back over to Bob.